Silencing of X-linked Inhibitor of Apoptosis Decreases Resistance to Cisplatin and Paclitaxel But Not Gemcitabine in Non-small Cell Lung Cancer

Author： Liu Y   Wu X   Sun Y   Chen F  

Publisher： Field House Publishing

ISSN： 0300-0605

Source： The Journal of International Medical Research, Vol.39, Iss.5, 2011-09, pp. : 1682-1692

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine in non-small cell lung cancer

By Cappuzzo Federico   Crinò Lucio  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 6, 2002-06 ,pp. : 745-753

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel for non-small cell lung cancer

By Ramalingam Sakkaraiappan   Belani Chandra P  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 8, 2004-08 ,pp. : 1771-1780

Informa Healthcare

Access to resources Recommend Favorite

Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer

By Vansteenkiste Johan   Canon Jean-Luc   Riska Henrik   Pirker Robert   Peterson Patrick   John William   Mali Pekka   Lahn Michael  

Investigational New Drugs, Vol. 23, Iss. 3, 2005-06 ,pp. : 263-269

Springer Publishing Company

Access to resources Recommend Favorite

Paclitaxel: A Pharmacoeconomic Review of its Use in Non-Small Cell Lung Cancer

By Plosker G.L.   Hurst M.  

PharmacoEconomics, Vol. 19, Iss. 11, 2001-11 ,pp. : 1111-1134

Adis International

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite